Clinical Trial Update: Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing ribociclib with endocrine therapy or chemotherapy, with or without bevacizumab, as first-line treatment for metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Chemotherapy (chemotherapy)
• Endocrine therapy
• Ribociclib (ribociclib)

Snippet

Sponsor: iOMEDICO AG | Conditions: Breast Cancer, Hormone Receptor Positive Tumor | Phase 3 | Status: COMPLETED